Medical Therapies for Children with Autism Spectrum Disorder—An Update
Project Summary Title and Description
- Medical Therapies for Children with Autism Spectrum Disorder—An Update
- This review was conducted to evaluate the comparative effectiveness and safety of medical interventions (defined broadly as interventions involving the administration of external substances to the body or use of external, non-behavioral procedures to treat symptoms of ASD) for children with Autism Spectrum Disorder (ASD). This report is a update on a previous report from 2011.
- Authors of Report
- Methodology description
- We included comparative studies of medical interventions that included at least 10 children with ASD between 2 and 12 years old. Two investigators independently screened studies and rated risk of bias. We extracted and summarized data qualitatively given significant heterogeneity. We also assessed strength of the evidence (SOE) and considered cumulative data from eligible studies included in our 2011 review of ASD therapies and newly published studies.
- Data entered retrospectively into SRDR. Outcome data,demographics data, and harms data files have been uploaded.
- Funding Source
- 1. KQ1: Among children ages 2-12 with ASD, what is the comparative effectiveness (benefits and harms) of medical treatments? a) What are the effects on core symptoms (e.g., deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities including hyper- or hypo- reactivity to sensory input or unusual interest in sensory aspects of the environment) in the short term (≤6 months)? b) What are the effects on commonly associated symptoms (e.g., motor, medical, mood/anxiety, irritability, and hyperactivity) in the short term (≤6 months)? c) What are the longer-term effects (>6 months) on core symptoms (e.g., social deficits, communication deficits, and repetitive behaviors)? d) What are the longer-term effects (>6 months) on commonly associated symptoms (e.g., motor, medical, mood/anxiety, irritability, and hyperactivity)?
- 2. KQ2: Among children ages 2-12 with ASD, what are the modifiers of outcome for different medical treatments? a. Is the effectiveness of the therapies reviewed affected by the frequency, duration, intensity, or dose of the intervention? b. Is the effectiveness of the therapies reviewed affected by co-interventions or prior treatment, or the training and/or experience of the individual providing the therapy? c. What characteristics (e.g., age, symptom severity), if any, of the child modify the effectiveness of the therapies reviewed? d. What characteristics, if any, of the family modify the effectiveness of the therapies reviewed?
- 3. KQ3: What is the time to effect of interventions?
- 4. KQ4: What is the evidence that effects measured at the end of the treatment phase predict long-term functional outcomes of interventions?
- 5. KQ5: Is the effectiveness of interventions maintained across environments or contexts (e.g., people, places, materials)?
- 6. KQ6: What evidence supports specific components of treatment as driving outcomes, either within a single treatment or across treatments?
Associated Extraction Forms
Associated Studies (each link opens a new tab)
Downloadable Data Content
- XLSX Project Data